Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Phase 3negativeNegative
AI Analysis
Summary
Novartis announced a late-stage trial failure for an Avidity-acquired drug in heart disease, marking the company's second significant setback in recent days.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Late-stage trial failure
Importance:8/10
Sentiment:
-0.90
trial failurelate-stageheart diseaseacquisitionnegative catalyst
Read the original article
Published by Endpoints News on September 8, 2026 8:24 AM